Short Interest in Tiziana Life Sciences Ltd (NASDAQ:TLSA) Increases By 300.2%

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 680,800 shares, a growth of 300.2% from the December 15th total of 170,100 shares. Based on an average daily volume of 348,300 shares, the short-interest ratio is currently 2.0 days. Currently, 1.0% of the shares of the company are sold short.

Hedge Funds Weigh In On Tiziana Life Sciences

An institutional investor recently raised its position in Tiziana Life Sciences stock. Zhang Financial LLC lifted its stake in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 69,387 shares of the company’s stock after purchasing an additional 13,500 shares during the period. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent quarter.

Tiziana Life Sciences Stock Performance

Shares of NASDAQ:TLSA opened at $0.75 on Tuesday. The firm’s 50 day moving average is $0.88 and its two-hundred day moving average is $0.95. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.